Concord Biotech Limited reported earnings results for the third quarter and nine months ended December 31, 2025. For the third quarter, the company reported sales was INR 2,777.66 million compared to INR 2,442.2 million a year ago. Revenue was INR 2,877.42 million compared to INR 2,589.5 million a year ago. Net income was INR 644.77 million compared to INR 759.21 million a year ago. Basic earnings per share from continuing operations was INR 6.08 compared to INR 7.26 a year ago.
For the nine months, sales was INR 7,288.11 million compared to INR 7,702.03 million a year ago. Revenue was INR 7,658.17 million compared to INR 8,052.66 million a year ago. Net income was INR 1,721.15 million compared to INR 2,312.55 million a year ago. Basic earnings per share from continuing operations was INR 16.32 compared to INR 22.11 a year ago.
Concord Biotech Limited is an India-based research and development-driven biopharmaceutical company focused on manufacturing fermentation-based active pharmaceutical ingredients (APIs) and formulations. The Company is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its product portfolio encompasses both biopharmaceutical APIs and formulations across various therapeutic areas, including immunosuppressants, oncology, anti-infectives, nephrology, and critical care. Its API products include Immunosuppressant, Oncology Drugs, Anti-bacterial, and others. Its Immunosuppressant include Tacrolimus, Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, and Voclosporin. Its Oncology Drugs include Temsirolimus, Everolimus, Romidepsin, Mitomycin, Dactinomycin, Midostaurin, and Doxorubicin. Its Anti-bacterial include Mupirocin, Mupirocin Calcium, Teicoplanin, and others.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
